Stock listing

Stockholm:ACE Ascelia Pharma AB Aktie

Home listing (Stockholm) of Ascelia Pharma AB

Follow Ascelia Pharma AB into a list and get an email when it puts out news.

Share price · OMXSTO:ACE

0.559 SEK -0.039 (-6.5%)

Close on Nov 20, 2026

Past year -80.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.553 – 0.592 SEKNov 20, 2026
Volume
164,727 sharesNov 20, 2026
Market cap
74.65M SEKAt the close on Nov 20, 2026 · price × 133.5M shares outstanding
52-week range
0.455 – 3.550 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
630,549 SEKMedian day 601,712 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Ascelia Pharma AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:ACE · Home0.559 SEK-0.039 (-6.5%)164,7270.5910.5920.5530.598Close on Nov 20, 2026
Frankfurt:7ZA€0.042 EUR-0.004 (-8.1%)—€0.045€0.045€0.042€0.046Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:ACE · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
0.559-0.039-6.5%0.5910.5920.553164,727
0.598+0.024+4.2%0.5740.6000.560319,076
0.574-0.026-4.3%0.6000.6000.56083,660
0.600+0.020+3.4%0.5800.6100.523602,521
0.580+0.047+8.8%0.5330.5900.519539,288
0.533+0.013+2.5%0.5190.5330.519276,377
0.520-0.038-6.8%0.5210.5340.516124,143
0.5580.0000.0%0.5590.6100.5241,229,881
0.558+0.047+9.2%0.5210.7610.5203,431,685
0.511-0.027-5.0%0.5380.5490.508885,584
0.538-0.018-3.2%0.5420.5500.530111,597
0.556-0.024-4.1%0.5800.5800.521319,481
0.5800.0000.0%0.5800.5880.550157,034
0.580+0.065+12.6%0.5220.5880.514768,378
0.515-0.005-1.0%0.5180.5320.512261,963
0.520-0.008-1.5%0.5410.5410.517422,042
0.528+0.008+1.5%0.5200.5500.511243,966
0.520+0.010+2.0%0.5200.5400.510176,030
0.510+0.004+0.8%0.5120.5700.510600,903
0.506-0.012-2.3%0.5190.5790.504480,174
0.518-0.017-3.2%0.5350.5350.507460,192
0.535-0.027-4.8%0.5620.6350.5351,086,850
0.562+0.024+4.5%0.5390.5800.539495,089
0.538-0.042-7.2%0.5710.5710.5101,414,855
0.580-0.095-14.1%0.6490.6490.5801,285,125
0.675-0.005-0.7%0.6800.6930.6011,085,173
0.680-0.180-20.9%0.6500.7030.5104,584,675
0.860+0.004+0.5%0.8380.8980.8001,569,400
0.856+0.156+22.3%0.7010.8900.7011,914,185
0.700-0.102-12.7%0.8020.8020.700756,786
0.802-0.018-2.2%0.8440.8440.782870,590
0.820+0.010+1.2%0.8410.9340.8003,460,165
0.810+0.011+1.4%0.7990.8550.7991,238,986
0.799+0.007+0.9%0.7870.9140.7722,627,116
0.792+0.161+25.5%0.6351.0580.6316,108,157
0.631-0.016-2.5%0.6460.6530.620745,979
0.647+0.004+0.6%0.6430.6620.630471,060
0.643+0.014+2.2%0.6290.6440.602455,596
0.629+0.009+1.5%0.6010.6450.601331,322
0.6200.0000.0%0.6200.6270.585457,906
0.620+0.012+2.0%0.6080.6390.597203,713
0.608-0.018-2.9%0.6270.6500.600638,607
0.626+0.053+9.2%0.5930.6490.573372,777
0.573-0.029-4.8%0.6150.6150.571329,679
0.602-0.020-3.2%0.6000.6320.600313,194
0.622+0.003+0.5%0.6170.6290.590441,588
0.619-0.018-2.8%0.6440.6510.612315,917
0.637-0.005-0.8%0.6400.6700.624558,050
0.642-0.016-2.4%0.6590.6590.631478,183
0.658+0.013+2.0%0.6450.6590.638377,243
0.645+0.003+0.5%0.6300.6480.620785,205
0.6420.0000.0%0.6420.6420.642739,283
0.642+0.012+1.9%0.6370.6460.621250,012
0.630+0.023+3.8%0.6070.6370.600828,846
0.607-0.008-1.3%0.6150.6150.5821,068,956
0.615-0.016-2.5%0.6300.6340.591897,025
0.6310.0000.0%0.6140.6310.611351,955
0.631+0.008+1.3%0.6030.6320.603683,348
0.623-0.003-0.5%0.6310.6390.6031,527,374
0.626+0.018+3.0%0.6240.6380.610677,149
0.608-0.007-1.1%0.6150.6400.6062,043,032
0.615+0.005+0.8%0.6100.6500.5982,270,121
0.610+0.020+3.4%0.5700.6170.5611,142,953
0.590+0.040+7.3%0.5980.5980.553748,708
Ticker
Stockholm:ACE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stockholm
Currency
SEK

What changed lately

Latest news

All Ascelia Pharma AB news

Ascelia Pharma AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 19 in all · newest Sep 24, 2026 · oldest 2025
Calls
10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
Decks
8 decks · latest Aug 20, 2026

Where Ascelia Pharma AB is listed

ListingExchangeCountryCurrency
Stockholm:ACE · Home listing · This pageStockholmSwedenSEK
Aquis:ACESAquisUnited KingdomSEK
Aquis:ACESAquisUnited KingdomSEK
Frankfurt:7ZAFrankfurtGermanyEUR

Valuation

Price/book 0.8× against a median of 2.4×: 4th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
37.09M SEK
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Ascelia Pharma AB · OMXSTO:ACEUS$7.30MUS$3.63Mn/an/an/a0.8×n/a0.0×n/a
Annexin Pharmaceuticals AB · OMXSTO:ANNXUS$7.59MUS$6.18Mn/an/an/a6.3×n/a0.0×n/a
Solvonis Therapeutics PLC · LSE:SVNSUS$7.57MUS$6.80Mn/an/an/a1.2×n/a0.0×n/a
Vistagen Therapeutics, Inc. · NASDAQ:VTGNUS$7.56M−US$11.87Mn/a−5.0×n/a0.5×n/a0.0×1.47
Noxopharm Ltd. · ASX:NOXUS$7.52MUS$10.36Mn/a11.0×n/an/a−312.2%n/an/a
AEON Biopharma, Inc. · AMEX:AEONUS$7.27M−US$4.15Mn/an/an/a3.0×n/a0.0×1.04
Pila Pharma AB · OMXSTO:PILAUS$7.01MUS$6.70Mn/an/an/a4.5×n/a0.0×n/a
Cadrenal Therapeutics, Inc. · NASDAQ:CVKDUS$7.01MUS$3.95Mn/an/an/a2.4×n/a0.0×1.60
Ensysce Biosciences, Inc. · NASDAQ:ENSCUS$7.00M−US$22.51Mn/a−3.6×n/a0.3×n/a0.0×1.28
Arctic Bioscience AS · OSL:ABSUS$7.00MUS$11.38Mn/a2.8×n/a0.4×−102.3%0.3×n/a
Alaunos Therapeutics, Inc. · NASDAQ:TCRTUS$6.99MUS$6.37Mn/a2,124×n/a7.2×n/a0.0×0.90
Median of the othersUS$7.14MUS$6.27M2.8×2.4×−207.2%0.0×1.28

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
1.93 SEK · Analysts' mean
EPS, year to Dec 2026
-0.13 · 2 analysts
Revenue, year to Dec 2026
26M · 3 analysts

Team and board

OfficerRole
Jennie WilborgssonChief Operating Officer

Events

Results days

QuarterResultsShare move
Q4 2025Feb 5, 2026 · Before open+6.0%
Q3 2025Nov 5, 2025 · Before open−1.9%
Q2 2025Aug 21, 2025 · Before open+3.7%
Q1 2025May 16, 2025 · Before open−2.1%
Q4 2024Feb 7, 2025 · Before open+5.6%
Q3 2024Nov 7, 2024 · Before open+12.9%
Q2 2024Aug 15, 2024 · Before open+14.5%
Q1 2024May 16, 2024 · Before open−6.7%
Q4 2023Feb 9, 2024 · Before open−4.8%
Q3 2023Nov 8, 2023 · Before open+2.0%
All 20 quarters
QuarterResultsShare move
Q2 2023Aug 18, 2023 · Before open−5.5%
Q1 2023May 11, 2023 · Before open−1.5%
Q4 2022Feb 10, 2023 · After close+0.8%
Q3 2022Nov 4, 2022 · Before open+10.7%
Q2 2022Aug 18, 2022 · Before open−2.6%
Q1 2022May 11, 2022 · Before open−3.1%
Q4 2021Feb 10, 2022 · Before open+1.6%
Q3 2021Nov 4, 2021 · Before open+4.6%
Quarter to Jun 30, 2021Aug 19, 2021 · Before open−4.8%
Quarter to Mar 31, 2021May 12, 2021 · Before open−0.9%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings24 slidesAug 20, 2026
Q4 2025 Earnings PresentationEarnings23 slidesFeb 5, 2026
Q3 2025 Earnings PresentationEarnings30 slidesNov 5, 2025
Q2 2025 Earnings PresentationEarnings26 slidesAug 22, 2025
Q1 2025 Earnings PresentationEarnings29 slidesMay 16, 2025
Q3 2024 Earnings PresentationEarnings33 slidesNov 7, 2024
Q2 2024 Earnings PresentationEarnings30 slidesAug 15, 2024
Q1 2024 Earnings PresentationEarnings40 slidesMay 16, 2024

Open Decks

Financings

RaiseDateIn US dollars
Private placement of ordinary shares
Announced: SEK 20M · SEK 3 a share · ABG Sundal Collier AB
Dealers: ABG Sundal Collier AB
Buyers: Salenia AB (existing shareholder); Mats Thorén (existing shareholder); Fredrik Lundgren; Wilhelm Risberg
Use of proceeds: Strengthen the balance sheet, enhance its position in partnering discussions for Orviglance and extend the cash runway into 2027
Apr 23, 2026US$2.17M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in SEK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue000000000
Cost of revenue888.0K938.0K1.05M3.89M8.72M825.0K62.0K2.51M
Gross profit00000-825.0K-62.0K-2.51M
Research and development56.8M50.8M81.3M118.1M107.6M64.8M26.9M15.6M9.37M
Selling, general and administrative6.48M18.0M19.8M14.6M8.81M18.3M18.0M6.59M16.4M
Operating income-74.4M-67.8M-110.9M-147.0M-137.9M-93.4M-36.7M-37.4M-24.7M
Depreciation and amortization888.0K938.0K1.05M1.05M1.03M825.0K62.0K5.00K24.7M
EBITDA-73.5M-66.8M-109.9M-146.0M-136.9M-92.6M-36.7M-37.4M-42.0K
Interest expense5.51M13.9M2.42M3.96M2.01M13.0K033.0K18.0K
Income before tax-76.7M-80.1M-109.6M-133.2M-129.5M-99.7M-40.0M-37.6M-24.7M
Income tax-468.0K-94.0K-319.0K-1.93M-3.62M-1.05M-90.0K-417.0K-351.0K
Net income-76.3M-80.0M-109.3M-131.2M-125.9M-98.7M-39.9M-37.1M-24.4M
Earnings per share, basic-0.67-1.48-3.24-3.77-3.82-3.76-1.83-2.16-1.08
Earnings per share, diluted-0.67-1.48-3.24-3.77-3.82

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents49.9M75.3M21.9M149.6M261.6M184.7M108.5M150.0M55.1M1.63M
Short-term investments1.00K075.7M75.1M-47.0K
Receivables3.93M5.68M580.0K4.53M5.56M2.83M1.42M3.93M1.06M20.5M
Inventory-6.08M6.79M8.28M2.96M-20.5M
Current assets53.9M83.7M28.9M160.9M274.6M196.3M192.9M230.1M59.1M23.3M
Property, plant and equipment52.0K15.0K89.0K163.0K238.0K1.99M212.0K275.0K0
Goodwill-57.0M
Total assets111.9M140.9M87.1M218.6M333.5M255.4M250.2M287.4M116.1M80.4M
Accounts payable2.04M4.73M1.52M15.9M6.15M3.88M5.24M4.27M634.0K643.0K
Current liabilities12.4M62.0M12.6M37.5M25.1M18.4M13.1M11.2M4.42M2.79M
Long-term debt00
Total debt1.04M25.4M1.06M484.0K1.66M1.78M215.0K146.0K
Total liabilities12.5M62.0M12.7M37.7M25.7M19.3M13.2M11.3M4.42M2.79M
Shareholders' equity99.5M78.9M74.3M180.9M307.8M236.1M237.1M276.1M111.7M77.6M
Shares outstanding113.4M54.0M33.7M34.8M33.0M26.3M21.8M17.2M22.6M22.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-72.3M-62.8M-126.8M-125.3M-116.6M-85.5M-36.9M-30.3M-21.0M
Capital spending-57.0K000-38.0K-397.0K-397.0K-397.0K-397.0K
Free cash flow-72.3M-62.8M-126.8M-125.3M-116.6M-85.9M-36.9M-30.3M-21.0M
Cash from investing-57.0K047.0K-65.0K-38.0K76.0M-75.0K-75.0M-75.0M
Cash from financing48.2M115.2M-936.0K-1.10M184.9M92.7M-60.0K200.2M74.4M
Share buybacks72.8M105.3M-89.0K-295-397.0K98.7M0222.1M80.4M
Change in cash-24.1M52.3M-127.7M-126.4M68.3M76.2M53.5M94.9M53.4M

Open Financials

Cap table

Built by 6ix from Ascelia Pharma AB’s releases · as of Apr 23, 2026

Common shares
133,535,460
Fully diluted
133,535,460

Fully diluted

LineShares
Common shares133,535,460

Share count over time

CountShares
Nov 22, 2026133,535,460

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Andreas Linderoth Norlin
Other senior executive
Buy25,000SEK 0.63SEK 15,750Sep 25, 2026
Andreas Linderoth Norlin
Other senior executive
Buy32,519SEK 0.64SEK 20,650Sep 25, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jennie WilborgssonChief Operating Officer · Since at least Nov 3, 2025

Open People

Log in to ask 6ix AI your own questions about Ascelia Pharma AB.